Trinity Net Debt vs Other Current Assets Analysis
TRIB Stock | USD 1.22 0.08 6.15% |
Trinity Biotech financial indicator trend analysis is much more than just breaking down Trinity Biotech plc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Trinity Biotech plc is a good investment. Please check the relationship between Trinity Biotech Net Debt and its Other Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Net Debt vs Other Current Assets
Net Debt vs Other Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Trinity Biotech plc Net Debt account and Other Current Assets. At this time, the significance of the direction appears to have no relationship.
The correlation between Trinity Biotech's Net Debt and Other Current Assets is 0.01. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Trinity Biotech plc, assuming nothing else is changed. The correlation between historical values of Trinity Biotech's Net Debt and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Trinity Biotech plc are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Net Debt i.e., Trinity Biotech's Net Debt and Other Current Assets go up and down completely randomly.
Correlation Coefficient | 0.01 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Most indicators from Trinity Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Trinity Biotech plc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. As of November 24, 2024, Selling General Administrative is expected to decline to about 23.8 M. In addition to that, Discontinued Operations is expected to decline to about (65.2 K)
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 93.0M | 74.8M | 56.8M | 78.6M | Depreciation And Amortization | 2.7M | 2.3M | 1.8M | 1.7M |
Trinity Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Trinity Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Trinity Biotech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 131.1M | 130.4M | 118.9M | 92.1M | 59.4M | 56.5M | |
Short Long Term Debt Total | 102.2M | 104.3M | 99.2M | 58.3M | 67.4M | 42.8M | |
Other Current Liab | (2.6M) | 9.6M | 7.9M | 9.1M | 8.9M | 4.7M | |
Total Current Liabilities | 19.4M | 27.1M | 100.5M | 17.3M | 15.0M | 22.6M | |
Total Stockholder Equity | 4.7M | (2.2M) | (319K) | (2.2M) | (23.9M) | (22.8M) | |
Property Plant And Equipment Net | 9.3M | 8.5M | 5.9M | 5.7M | 1.9M | 1.8M | |
Net Debt | 65.6M | 77.0M | 73.2M | 51.7M | 63.7M | 66.9M | |
Retained Earnings | 11.5M | 10.6M | 12.6M | (26.7M) | (48.6M) | (46.2M) | |
Accounts Payable | 19.4M | 7.1M | 6.8M | 6.2M | 3.9M | 3.7M | |
Cash | 16.4M | 27.3M | 25.9M | 6.6M | 3.7M | 3.5M | |
Non Current Assets Total | 59.7M | 47.1M | 46.2M | 45.4M | 20.4M | 19.4M | |
Non Currrent Assets Other | 82K | 64K | 56K | 55K | 43K | 40.9K | |
Cash And Short Term Investments | 16.4M | 27.3M | 25.9M | 6.6M | 3.7M | 3.5M | |
Net Receivables | 23.0M | 24.6M | 15.7M | 13.4M | 13.4M | 18.1M | |
Common Stock Shares Outstanding | 5.1M | 4.2M | 5.3M | 7.8M | 7.7M | 6.8M | |
Liabilities And Stockholders Equity | 131.1M | 130.4M | 118.9M | 92.1M | 59.4M | 56.5M | |
Non Current Liabilities Total | 106.9M | 105.6M | 18.7M | 76.9M | 68.3M | 39.2M | |
Inventory | 32.0M | 30.2M | 29.1M | 22.5M | 19.9M | 25.5M | |
Other Current Assets | 23.0M | 1.2M | 1.9M | 4.1M | 2.0M | 3.9M | |
Total Liab | 126.4M | 132.6M | 119.2M | 94.3M | 83.4M | 61.7M | |
Total Current Assets | 71.4M | 83.3M | 72.7M | 46.7M | 39.0M | 69.5M | |
Short Term Debt | 2.4M | 5.1M | 85.3M | 1.9M | 1.9M | 1.8M | |
Intangible Assets | 31.1M | 21.3M | 23.4M | 22.7M | 16.3M | 15.5M | |
Property Plant And Equipment Gross | 9.3M | 8.5M | 63.5M | 65.6M | 66.1M | 69.4M | |
Accumulated Other Comprehensive Income | (24.2M) | (5.3M) | (5.4M) | (5.7M) | 1.0M | 1.1M | |
Long Term Debt | 81.4M | 82.0M | 83.9M | 58.0M | 54.7M | 44.0M | |
Property Plant Equipment | 5.4M | 9.3M | 8.5M | 5.9M | 5.3M | 9.6M | |
Other Liab | 8.1M | 7.1M | 6.3M | 4.9M | 5.6M | 6.2M | |
Current Deferred Revenue | 292K | 4.4M | 141K | 114K | 50K | 47.5K | |
Other Assets | 33.0M | 29.5M | 18.1M | 4.3M | 5.0M | 4.7M | |
Net Tangible Assets | 17.4M | (16.2M) | (22.6M) | (36.3M) | (32.7M) | (31.0M) | |
Deferred Long Term Liab | 26.3M | 22.8M | 13.4M | 17.7M | 15.9M | 15.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.